Canada · Delayed Price · Currency is CAD BioSyent Statistics
Total Valuation
BioSyent has a market cap or net worth of CAD 165.71 million. The enterprise value is 137.90 million.
| Market Cap | 165.71M |
| Enterprise Value | 137.90M |
Important Dates
The last earnings date was Thursday, March 19, 2026.
| Earnings Date | Mar 19, 2026 |
| Ex-Dividend Date | Feb 27, 2026 |
Share Statistics
BioSyent has 11.50 million shares outstanding. The number of shares has decreased by -2.55% in one year.
| Current Share Class | 11.50M |
| Shares Outstanding | 11.50M |
| Shares Change (YoY) | -2.55% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 11.22% |
| Owned by Institutions (%) | 19.30% |
| Float | 9.12M |
Valuation Ratios
The trailing PE ratio is 18.40 and the forward PE ratio is 15.33.
| PE Ratio | 18.40 |
| Forward PE | 15.33 |
| PS Ratio | 3.85 |
| PB Ratio | 4.00 |
| P/TBV Ratio | 4.50 |
| P/FCF Ratio | 18.48 |
| P/OCF Ratio | 18.39 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.47, with an EV/FCF ratio of 15.37.
| EV / Earnings | 15.30 |
| EV / Sales | 3.20 |
| EV / EBITDA | 11.47 |
| EV / EBIT | 12.32 |
| EV / FCF | 15.37 |
Financial Position
The company has a current ratio of 5.51, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.51 |
| Quick Ratio | 4.59 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.09 |
| Interest Coverage | 226.79 |
Financial Efficiency
Return on equity (ROE) is 23.57% and return on invested capital (ROIC) is 54.00%.
| Return on Equity (ROE) | 23.57% |
| Return on Assets (ROA) | 15.41% |
| Return on Invested Capital (ROIC) | 54.00% |
| Return on Capital Employed (ROCE) | 26.51% |
| Weighted Average Cost of Capital (WACC) | 7.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.95 |
| Inventory Turnover | 1.72 |
Taxes
In the past 12 months, BioSyent has paid 3.02 million in taxes.
| Income Tax | 3.02M |
| Effective Tax Rate | 25.09% |
Stock Price Statistics
The stock price has increased by +45.56% in the last 52 weeks. The beta is 0.65, so BioSyent's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +45.56% |
| 50-Day Moving Average | 14.69 |
| 200-Day Moving Average | 12.49 |
| Relative Strength Index (RSI) | 41.60 |
| Average Volume (20 Days) | 5,104 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSyent had revenue of CAD 43.05 million and earned 9.01 million in profits. Earnings per share was 0.78.
| Revenue | 43.05M |
| Gross Profit | 32.96M |
| Operating Income | 11.19M |
| Pretax Income | 12.03M |
| Net Income | 9.01M |
| EBITDA | 11.89M |
| EBIT | 11.19M |
| Earnings Per Share (EPS) | 0.78 |
Balance Sheet
The company has 28.65 million in cash and 841,104 in debt, with a net cash position of 27.81 million or 2.42 per share.
| Cash & Cash Equivalents | 28.65M |
| Total Debt | 841,104 |
| Net Cash | 27.81M |
| Net Cash Per Share | 2.42 |
| Equity (Book Value) | 41.47M |
| Book Value Per Share | 3.68 |
| Working Capital | 32.58M |
Cash Flow
In the last 12 months, operating cash flow was 9.01 million and capital expenditures -39,669, giving a free cash flow of 8.97 million.
| Operating Cash Flow | 9.01M |
| Capital Expenditures | -39,669 |
| Depreciation & Amortization | 700,345 |
| Net Borrowing | -196,627 |
| Free Cash Flow | 8.97M |
| FCF Per Share | 0.78 |
Margins
Gross margin is 76.57%, with operating and profit margins of 26.00% and 20.93%.
| Gross Margin | 76.57% |
| Operating Margin | 26.00% |
| Pretax Margin | 27.94% |
| Profit Margin | 20.93% |
| EBITDA Margin | 27.63% |
| EBIT Margin | 26.00% |
| FCF Margin | 20.83% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 1.53%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 1.53% |
| Dividend Growth (YoY) | 10.81% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 26.18% |
| Buyback Yield | 2.55% |
| Shareholder Yield | 4.06% |
| Earnings Yield | 5.44% |
| FCF Yield | 5.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSyent has an Altman Z-Score of 13.04 and a Piotroski F-Score of 5.
| Altman Z-Score | 13.04 |
| Piotroski F-Score | 5 |